Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12904-12916

  Puchades Carrasco, Leonor ^a   Jantus Lewintre, Eloisa ^b   Pérez Rambla, Clara ^a,b,c   García García, Francisco ^a   Lucas, Rut ^b   Calabuig, Silvia ^b   Blasco, Ana ^b   Dopazo, Joaquín ^a,d   Camps, Carlos ^b,e   Pineda Lucena, Antonio ^a,c  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Biomarkers; Early diagnosis; Metabolomics; NSCLC; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; GLUTAMINE; LACTIC ACID; METHANOL; THREONINE; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOPHYSIOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; AGED; BLOOD; DISEASE EXACERBATION; LUNG TUMOR; PATHOLOGY; PROCEDURES;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METABOLOMICS; MIDDLE AGED; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84962874763     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7354     Document Type: Article

References (53)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer Journal international du cancer. 2015; 136:E359-386.
2. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging C and Participating I. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology. 2007; 2:706-714.
3. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine. 2011; 365:395-409.
4. Jantus-lewintre E, Usó M, Sanmartín, E, Camps C. Update on biomarkers for the detection of lung cancer. Lung Cancer: Targets and Therapy. 2012; :1-9.
5. Holmes E, Wilson ID and Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008; 134:714-717.
6. Puchades-Carrasco L and Pineda-Lucena A. Metabolomics in pharmaceutical research and development. Curr Opin Biotechnol. 2015; 35:73-77.
7. Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, Hayashi N, Kawano S, Fujiwara Y, Minami H, Takenawa T, Azuma T, et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer epidemiology, biomarkers & prevention. 2013; 22:571-579.
8. Kind T, Tolstikov V, Fiehn O and Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancer. Analytical biochemistry. 2007; 363:185-195.
9. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM and Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Molecular & cellular proteomics : MCP. 2009; 8:558-570.
10. Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Chiorean EG and Raftery D. Colorectal cancer detection using targeted serum metabolic profiling. Journal of proteome research. 2014; 13:4120-4130.
11. Urayama S, Zou W, Brooks K and Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid communications in mass spectrometry : RCM. 2010; 24:613-620.
12. Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, McDonald JF and Fernandez FM. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC bioinformatics. 2009; 10:259.
13. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S and Alderfer JL. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. International journal of cancer Journal international du cancer. 2005; 113:782-788.
14. Tiziani S, Lopes V and Gunther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia. 2009; 11:269-276, 264p following 269.
15. MacIntyre DA, Jimenez B, Lewintre EJ, Martin CR, Schafer H, Ballesteros CG, Mayans JR, Spraul M, Garcia-Conde J and Pineda-Lucena A. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia. 2010; 24:788-797.
16. Puchades-Carrasco L, Lecumberri R, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Prosper F, San-Miguel JF and Pineda-Lucena A. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clinical cancer research. 2013; 19:4770-4779.
17. Nobakht MGBF, Aliannejad R, Rezaei-Tavirani M, Taheri S and Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers. 2015; 20:5-16.
18. Rocha CM, Carrola J, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L and Duarte IF. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. Journal of proteome research. 2011; 10:4314-4324.
19. Carrola J, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L and Duarte IF. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. Journal of proteome research. 2011; 10:221-230.
20. Deja S, Porebska I, Kowal A, Zabek A, Barg W, Pawelczyk K, Stanimirova I, Daszykowski M, Korzeniewska A, Jankowska R and Mlynarz P. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. Journal of pharmaceutical and biomedical analysis. 2014; 100:369-380.
21. Jordan KW, Adkins CB, Su L, Halpern EF, Mark EJ, Christiani DC and Cheng LL. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung cancer. 2010; 68:44-50.
22. Wang L, Tang Y, Liu S, Mao S, Ling Y, Liu D, He X and Wang X. Metabonomic profiling of serum and urine by (1)H NMR-based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. PloS one. 2013; 8:e65675.
23. Johnson WE, Li C and Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8:118-127.
24. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL and Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer prevention research. 2012; 5:992-1006.
25. Body JJ. Metabolic sequelae of cancers (excluding bone marrow transplantation). Curr Opin Clin Nutr Metab Care. 1999; 2:339-344.
26. Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, Tedde A, Desogus A and Muntoni S. Serum lipoproteins and cancer. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2009; 19:218-225.
27. Banez-Coronel M, Ramirez de Molina A, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, Garcia-Cabezas MA, Garcia-Oroz L and Lacal JC. Choline kinase alpha depletion selectively kills tumoral cells. Current cancer drug targets. 2008; 8:709-719.
28. Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J and Lacal JC. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PloS one. 2009; 4:e7819.
29. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK and Keun HC. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). Journal of proteome research. 2009; 8:352-361.
30. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H and Deng F. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. Journal of proteome research. 2007; 6:2605-2614.
31. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314.
32. Lai HS, Lee JC, Lee PH, Wang ST and Chen WJ. Plasma free amino acid profile in cancer patients. Seminars in cancer biology. 2005; 15:267-276.
33. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, Daimon T, Yamakado M, Imamura F and Kodama K. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC cancer. 2010; 10:690.
34. Pisters PW and Pearlstone DB. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Critical reviews in clinical laboratory sciences. 1993; 30:223-272.
35. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, Bhakoo KK, Jayapal SR, Nichane M, Yu Q, Ahmed DA, Tan C, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012; 148:259-272.
36. Long F, Su JH, Liang B, Su LL and Jiang SJ. Identification of Gene Biomarkers for Distinguishing Small-Cell Lung Cancer from Non-Small-Cell Lung Cancer Using a Network-Based Approach. BioMed research international. 2015; 2015:685303.
37. Gao H, Dong B, Liu X, Xuan H, Huang Y and Lin D. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Analytica chimica acta. 2008; 624:269-277.
38. Zira AN, Theocharis SE, Mitropoulos D, Migdalis V and Mikros E. (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. Journal of proteome research. 2010; 9:4038-4044.
39. Eigenbrodt E, Kallinowski F, Ott M, Mazurek S and Vaupel P. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer research. 1998; 18:3267-3274.
40. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, Novelli F and Petricoin EF. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. Journal of proteome research. 2012; 11:554-563.
41. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P and Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014; 6:221ra215.
42. Mathe EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, Bowman ED, Shields PG, Idle JR, Smith PB, Anami K, Kazandjian DG, Hatzakis E, Gonzalez FJ and Harris CC. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer research. 2014; 74:3259-3270.
43. Neri B, Bartalucci S, Gemelli MT, Tommasi M and Bacalli S. Creatine kinase isoenzyme BB: a lung cancer associated marker. Int J Biol Markers. 1988; 3:19-22.
44. Gazdar AF, Zweig MH, Carney DN, Van Steirteghen AC, Baylin SB and Minna JD. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer research. 1981; 41:2773-2777.
45. Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, Spraul M, Carreira IM, Melo JB, Bernardo J, Gomes A, Sousa V, Carvalho L and Duarte IF. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. Journal of proteome research. 2010; 9:319-332.
46. Greene FL, Page D.L, Fleming I.D, Fritz A.G, Balch C.M, Haller D.G, Morrow, M. (2003). AJCC Cancer Staging Manual, 6th edition. (Philadelphia: Lippincott Raven Publishers).
47. Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Taron M, Berrocal A, Blasco S, Caballero C, Del Pozo N, Rosell R and Camps C. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. Clinical lung cancer. 2011; 12:224-230.
48. Jantus-Lewintre E, Sirera R, Cabrera A, Blasco A, Caballero C, Iranzo V, Rosell R and Camps C. Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients. Clinical lung cancer. 2011; 12:320-327.
49. Meiboom S GD. Modified spin-echo method for measuring nuclear relaxation times. The Review of scientific instruments. 1958; 29:688-701.
50. Nicholson JK, Foxall PJ, Spraul M, Farrant RD and Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Analytical chemistry. 1995; 67:793-811.
51. Lindon JC TG, Koppenaal D. (2010). Encyclopedia of spectroscopy and spectrometry. (London: Academic Press).
52. Leek JT, Johnson WE, Parker HS, Jaffe AE and Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28:882-883.
53. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria. 2013; http://www.R-project.org/